Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...

Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are ...

Novo Nordisk A/S (NVO) has slashed prices for its blockbuster weight-loss drug Wegovy as competition in the obesity drug market heats up, with ...

Novo Nordisk (NVO) warns U.S. tariffs on pharmaceuticals may lead to drug shortages & price hikes. Read more here.

Novo Nordisk says many Australians would be willing to pay the out-of-pocket costs for its blockbuster medicines, which can ...

Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...

Novo Nordisk NVO announced that it is launching a new direct-to-patient online pharmacy called NovoCare, which will offer its ...

Investing.com -- Shares of Novo Nordisk (NYSE: NVO) tumbled 6% today, following the announcement of results from its REDEFINE 2 phase 3 trial. Despite meeting its primary endpoint, showing ...

Novo Nordisk's NovoCare will now provide uninsured or underinsured patients access to Wegovy for just $499 per month—less ...

Novo Nordisk NVO announced that it is launching ... in December 2024 after determining that Lilly’s supply is currently meeting or exceeding demand and will continue to do so in the future.

In an exclusive conversation with Business Today, Camilla Sylvest, Executive Vice President, Commercial Strategy & Corporate ...